JAMA Oncology

AI summary · may contain errors

Perioperative camrelizumab plus chemotherapy improved 2-year event-free survival to 77.8% versus 46.1% in resectable stage III–IVB head and neck squamous cell carcinoma.

AI summary · may contain errors

Early oral nutritional supplementation at CCRT start in stage II–IVA nasopharyngeal carcinoma patients reduced >5% weight loss by completion (65.4% vs 80.7%; RR 0.81).

AI summary · may contain errors

Updated findings from the IDEA nonrandomized clinical trial report on treatment options for postmenopausal patients with estrogen receptor–positive breast cancer after radiotherapy omission in younger patients.

AI summary · may contain errors

Lack of standardization across next-generation sequencing methodologies is a key barrier to precision oncology, limiting reliable genome-informed decisions.

AI summary · may contain errors

A PDTC-specific TNM staging system reclassifies level VII lymph node metastasis and improves prognostic discrimination, with C statistics rising from 0.71 to 0.74 in the IATCCG cohort.

AI summary · may contain errors

HB0025 plus chemotherapy produced confirmed objective response rates of 36.4% and 57.1% in previously untreated driver variant-negative nonsquamous advanced NSCLC, with manageable toxicity.

AI summary · may contain errors

URiM representation among oncology and cancer-care physician trainees rose from 16.4% in 2020 to 20.4% in 2025, with the largest post-2020 jump in radiation oncology.

AI summary · may contain errors

Trastuzumab deruxtecan plus pertuzumab in ERBB2-positive metastatic breast cancer is linked to superior progression-free survival in DESTINY-Breast09, supporting FDA approval and reshaping first-line sequencing questions.

AI summary · may contain errors

HLA restrictions limit the applicability of T-cell receptor therapies across genetically diverse human populations, creating fairness challenges that stakeholders must address.

AI summary · may contain errors

FGFR2/3 alterations are clinically actionable biomarkers across non-muscle-invasive, muscle-invasive, metastatic, and upper-tract urothelial carcinoma, supporting precision oncology strategies.

AI summary · may contain errors

A Brazilian oncologist’s reaction to new daraxonrasib data is described through four encounters, highlighting how emerging evidence is received.

AI summary · may contain errors

Dose optimization and pragmatic de-escalation are presented as strategies for financially constrained health systems to make care more efficient without compromising appropriate use.

AI summary · may contain errors

Benmelstobart plus anlotinib improved independent review committee–assessed progression-free survival to a median 15.1 months versus 4.2 months with placebo in unresectable stage III NSCLC.

AI summary · may contain errors

In 2023, global malignant bone cancer burden included 111 000 cases, 76 600 deaths, and 3.02 million DALYs, with age-specific peaks and regional ASR disparities.

AI summary · may contain errors

In immune-positive, ERBB2-negative stage II/III early breast cancer in I-SPY2.2, RT-DXd achieved a modeled 54% pathologic complete response rate, meeting the predefined success threshold.

AI summary · may contain errors

Five-year outcomes after a de-escalated 30-Gy elective nodal irradiation regimen during definitive concurrent chemoradiotherapy are reported for patients with HPV-associated oropharyngeal carcinoma.

AI summary · may contain errors

Earlier follow-up is recommended for low-risk but measurable ovarian lesions classified by the Ovarian-Adnexal Reporting and Data System, to improve ongoing monitoring.